Introduction
Aplastic anemia (AA) is a hematopoietic stem cell disorder characterized by pancytopenia and hypocellular bone marrow in the absence of an abnormal infiltrate and no increase in reticulin. The incidence of acquired AA in Europe and North America is around 2 per million per year and two-to threefold higher in Asia [1, 2] . Hematopoietic stem cell transplant and immunosuppressive therapy (IST) are the primary modalities of treatment for AA. The efficacy of Immunosuppressive therapy (IST) in AA is well established since the 1970s, with several large prospective trials in the United States, Europe and Japan showing consistent results [3] [4] [5] . An effective IST regimen is equine anti-thymocyte globulin (eATG) in combination with cyclosporine which produces hematologic responses in 60-75 % of cases [1, 6] .
The present study was conducted to confirm the safety and efficacy of an indigenously developed eATG along with cyclosporine in Indian subjects with acquired aplastic anemia.
Methods
The indigenous eATG (Thymogam, manufactured by Bharat Serums and Vaccines Ltd. India.) was manufactured from healthy horses immunized with purified thymocytes obtained from children, below the age of 13 years, undergoing cardiac surgery. Plasmapheresis was carried out on horses showing appropriate titre of ATG, using lymphocytotoxicity assay. The hyperimmune plasma from several horses was pooled and fractionated using caprylic acid precipitation, followed by column chromatography, under GMP conditions to obtain highly purified IgG fraction, complying with the British Pharmacopoeia.
This phase IV, single group, prospective, multicentre study was conducted in subjects with acquired aplastic anemia of any severity at six centres across India between April 2011 and August 2013. The study protocol was approved by the institutional ethics committees at each centre.
Subjects aged above 2 years (children defined below 12 years of age), with acquired AA of any severity were eligible for enrolment. All subjects underwent standard investigations (complete hemogram, bone marrow aspiration and biopsy, liver and renal serum chemistries, plasma glucose, chest X-ray, electrocardiogram, hepatitis B, C and HIV serology and paroxysmal nocturnal hemoglobinuria). Subjects with Fanconi anemia (by chromosomal breakage studies), history of cancer, serum creatinine values more than 2.5 times upper limit of normal, seropositive for HIV, clonal disorders and pregnant women were excluded.
AA was defined as marrow cellularity of less than 25 % of normal or less than 50 % with haematopoietic cells representing less than 30 % of the residual cells and at least two of the following peripheral blood counts: neutrophil count of less than 0.5 9 10 9 /L, platelet count of less than 20 9 10 9 /L, and reticulocyte count of less than 1 % [6] .
The disease severity was classified as non severe aplastic anaemia (NSAA) with Hb less than 10 g/dL, neutrophil count less than 1.5 9 10 9 /L and platelet count less than 100 9 10 9 /L; severe aplastic anaemia (SAA) with 2 of the following neutrophil count less than 0.5 9 10 9 /L, platelet count less than 20 9 10 9 /L and reticulocyte count less than 1 % and very severe aplastic anaemia (VSAA) with absolute neutrophil count less than 0.2 9 10 9 /L [7] . Enrolled subjects received eATG at a dose of 40 mg/kg/ day for 4 days, administered as an IV infusion over 12 h, after sensitivity testing with 0.1 ml of eATG. Premedication, prophylactic antimicrobials and supportive care (blood and platelet transfusion) was provided as per individual hospital protocol. Cyclosporine (CSA) was administered at a dose of 4-6 mg/kg/day of eATG infusion to maintain trough levels of 200-400 ng/mL for 6 months duration of study. The actual dose given as well as the commencement or continuation of the CSA was as per investigator's discretion. There was no tapering of CSA during the study. Granulocyte Colony Stimulating Factor (G-CSF) was given after e ATG in 2 subjects: 1 (VSAA) on day 5, 6 and 7 showed partial response and 1 (SAA) on day 31 and 32 was non-responder. Subjects were called for follow-up on days 14, 21, 30, 45, 90 and 180 after first dose of eATG for clinical examination and laboratory investigations. End-of-study was on day 180 after first dose of eATG.
The trial was registered with the Clinical Trial RegistryIndia (Registration no. CTRI/2012/03/002498).
Efficacy Assessment
Response was graded as complete response (CR) or partial response (PR) as recommended by British Committee for Standards in Haematology (2009) guidelines (Table 1) [6] . Clinical examination and laboratory investigations (hemogram, liver and renal serum chemistries) were performed daily during eATG administration and then on each Table 1 Response criteria in aplastic anemia according to British Committee for Standards in Haematology guidelines [7] Response in aplastic anemia Criteria follow-up visit till day 180 end-of-study visit. Relapse was defined as reversal to transfusion dependence after partial or complete response. Subjects blood was also analysed for T lymphocyte subsets on pre eATG infusion (day 0) and on days 3, 5, 7, 14 and 21 after first dose of eATG at a centralized lab. Blood samples were collected from the sites and couriered to the central laboratory within 8 h for testing. Counts for CD2, CD3, CD4 and CD8 were determined by Flow Cytometry (FACS Calibur; Becton-Dickinson) with immunofluorescent monoclonal antibodies (Phycoerythrin Mouse Anti Human CD2, Fluorescein Isothiocyanate Mouse Anti Human CD4, Fluorescein Isothiocyanate Mouse Anti Human CD3, Fluorescein Isothiocyanate Mouse Anti Human CD8; Becton-Dickinson). 100 ll blood was incubated with 10 ll of the Fluorescent Antibody at room temperature for 15 min in the dark. 2 ml of 19 Lysing solution (BD FACS Lysing Solution 109; Becton-Dickinson) was added to each tube and the same was incubated at room temperature for 15 min in the dark. Tubes were spun at 1500 rpm for 5 min, after which the supernatant was discarded and the tubes were washed once with 2 ml of Sheath Fluid (BD FACS Flow; BectonDickinson). The cells were re-suspended in 300 ll of Sheath Fluid and 10,000 events were read on the flow cytometer. CD counts were analysed by comparing the percent gated cells with the absolute lymphocyte count.
Safety Assessment
All subjects were regularly monitored for adverse events (AE) till completion of study. Infusion related events were monitored during eATG infusion daily. Adverse events were assessed for their seriousness and their relationship to eATG.
Statistical Analysis
The analysis of data was performed by an independent biostatistician. For categorical data, frequency counts (n) and percentage (%) was presented. Changes in subject variables throughout the study duration are presented as median with further analysis using repeated measure ANOVA test.
Results
Of the 30 subjects recruited, 20 were male. The median (range) age of the subjects was 30 (9-58) years and weight was 57 (26-84) kg. The median (range) duration from diagnosis of AA to start of eATG administration was 3 (1-24) months. Eight subjects had non-severe aplastic anemia (NSAA), 17 had severe aplastic anemia (SAA) and five had very severe aplastic anemia (VSAA).
Twenty-eight subjects received complete four doses of eATG. One subject developed jaundice after first dose of eATG and was withdrawn from the study by the investigator. One subject had an adverse event (acute renal failure) on day 3 hence the 4 th day dose was not given; this subject completed day 180 follow up. Nineteen subjects followed up till day 90 and 18 till day 180 (one subject lost to follow up post day 90). Among those who did not complete day 90 follow up, two subjects died (on day 12 and 45) and eight were lost to follow-up. These eight patients were discharged and did not return for subsequent follow-ups: two of them withdrew consent telephonically and six were not reachable despite repeated attempts by telephone and by study co-ordinator visits to the address given by the patients, from where they had moved without any forwarding address available.
At 90 day follow-up, one subject had complete response (CR) and 11 subjects showed partial response (PR) (total response-12 of 30). At 180 days, two subjects had CR and 13 had PR (total response-15 of 30). The response to treatment in subjects with NSAA, SAA and VSAA is summarized in Table 2 . This included two children; one child with SAA showed partial response on day 180 and one VSAA was lost to follow up after completing 4 days of eATG treatment.
The mean dose of CSA prescribed to subjects enrolled in the study was 4.5 mg/kg body weight. The median (range) was 3.23 (1.9-6.6). The decision on actual dose was left to the investigator's discretion. Time to commencement of CSA as advised in the protocol was 2 weeks after last dose of ATG but five of 29 patients were already on CSA prior to enrollment in the study and this was not discontinued; in three patients CSA was commenced within 10 days after eATG administration. Balance 21 patients commenced CSA 2 weeks after last dose of eATG. 28 of 30 patients were given premedication with steroids during the 4 days NR non-responders, CR complete responders, PR partial responders, NSAA non-severe aplastic anemia, SAA severe aplastic anemia, VSAA very severe aplastic anemia of eATG administration (four subjects each received methylprednisolone and dexamethasone and 20 subjects received hydrocortisone). For serum sickness prophylaxis, the patients were given oral prednisone 1 mg/kg/day prior to the first dose of ATG and continued for 10 days and then tapered over the subsequent 7 days. Antimicrobial prophylaxis was given as per hospital practice to the patients-25 of the 30 subjects received antibacterial; 19 of these 25 received antifungal and seven also received antiviral prophylaxis in addition. Therapeutic antibiotics were administered to five patients for eight events (fever (five) and one each of abscess/urinary tract infection/gingivitis). G-CSF was given after e ATG in two patients; one patient (VSAA) received G-CSF on days 5-7 after commencement of eATG and showed partial response and one patient (SAA) received G-CSF on days 31 and 32 but did not respond to treatment.
The median duration between diagnosis of AA and institution of IST was 3 (1-24) months in the responders and 10 (3-10) months in the non-responders. The blood T cell subset counts decreased by 91 % by day 5 and recovered completely by day 21 in all subjects (Fig. 1) .
A total of 79 non-serious adverse events were reported of which 28 were eATG related and 51 were unrelated. (Table 3 ). Of these, 26 occurred during eATG infusion (16 related); 53 occurred post eATG infusion (12 related). Fever (15 subjects) was the most common adverse event reported followed by vomiting (five subjects). Anorexia (three subjects) was seen only post eATG administration. All these non-serious adverse events recovered without any sequelae.
Serious adverse events were noted in five subjects. One subject developed acute renal failure on day 3 which resolved completely by day 30 after receiving standard treatment. One subject was readmitted for febrile neutropenia on day 30 for 3 days and discharged on recovery. One subject had seizure with no apparent cause and recovered. There were two deaths; one subject died at home on day 45 due to unresolved pneumonia and one subject died on day 12 due to septicemia.
Discussion
We assessed the safety and efficacy of indigenously developed eATG in 30 Indian subjects with acquired aplastic anemia at six centres across India. Eight subjects were lost to follow up mainly because many changed their address or moved to hometowns in remote places and did not adhere to follow up visit dates. This, along with two cases of early deaths, one withdrawn after first dose of eATG, left 19 subjects who completed day 90 follow up and 18 subjects with day 180 follow-up (one lost to followup after day 90).
For ITT analysis, the subjects who were lost to follow-up were considered as non responders. ITT analysis revealed a response in 12 of 30 subjects (40 %) at or before day 90 and 15 of 30 (50 %) at day 180 post eATG administration along with cyclosporin. The total number of subjects was small, but the results are in accordance with earlier studies which have reported response rates of 33-85 % [3, 5, [8] [9] [10] [11] [12] [13] [14] [15] [16] . The findings of various Indian studies have been summarised in Table 4 . The response rate of 50 % in our study is distributed across all severity groups supporting the use of eATG in subjects with AA of any severity.
ATG is a polyclonal antibody that recognises various antigens on the cell surface membranes and is cytotoxic to lymphocytes in vitro. The immunosuppressive effect is mediated through lymphocyte depletion, modulation or coating. ATG is reported to have activity against CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD11a, CD16, CD18, CD28, CD38, CD40, CD44 and CD 45 and T cell receptors a/b antigens. CD2, CD3 and CD4 and CD8 counts tested in our study were seen to fall between days 3 and 5 after eATG administration and recover between days 7 and 14. This confirms the action of eATG on T cell-mediated immunity and in our study this result was seen in every patient irrespective of the clinical response on day 180.
The duration between diagnosis of AA and institution of IST was greater in the non-responders than in the responders. This emphasizes the need to start therapy early in the course of the disease. Eighteen of 30 (60 %) of those treated with eATG were still surviving at the last postprotocol follow-up (November 2013).
A total of five serious adverse events were reported, including two deaths. Both the deaths resulted from infective pathology (pneumonia and septicemia). The three other SAEs-acute renal failure, febrile neutropenia and seizures resolved with medical management. All the 79 non-serious adverse events reported in the study resolved with supportive care and there were no unknown adverse effects. Some of the adverse events may be related to administration of corticosteroids and cyclosporine or due to basic disease and not necessarily related to eATG administration.
In conclusion, this study demonstrates that immunosuppression with eATG developed indigenously by Bharat Serum and Vaccine Ltd, India, in combination with cyclosporine, is safe and effective first line therapy in subjects with AA who are unsuitable for hematopoietic stem cell transplantation.
